超短程糖皮质激素后托珠单抗单药治疗巨细胞动脉炎的疗效:三年随访
GUSTO试验评估新发巨细胞动脉炎患者接受3天甲泼尼龙静脉冲击后52周托珠单抗单药治疗的3年维持效果。18例患者中,第52周13例无复发生存进入随访,第208周11例维持无复发缓解,11/13例停药后无复发缓解持续156周。
要点
- 18例新发巨细胞动脉炎患者接受500 mg甲泼尼龙静脉冲击3天,随后托珠单抗单药治疗至第52周。
- 第52周13/18例无复发缓解并进入随访,第208周11/18例维持无复发缓解,11/13例药物-free缓解持续156周。
- 2例轻度复发(第72、187、200周)重启托珠单抗单药治疗后均再获缓解。
核心结论
- 进入长期扩展研究的患者中除2例外均维持药物-free缓解,复发率低于随机对照试验报告。
- 作者认为患者特征(均为新诊断)和强化初始治疗可能解释持久缓解。
研究设计与样本
- 单臂、单中心、开放标签临床试验,纳入18例新诊断巨细胞动脉炎患者。
- 患者接受500 mg甲泼尼龙静脉冲击3天,第3天起至第52周接受托珠单抗单药治疗,临床缓解者第52周停用托珠单抗。
- 主要维持疗效指标为第208周完全持久缓解的患者比例。
主要发现
- 纳入时中位年龄72岁(四分位距67-75),15/18例有颅部症状。
- 第52周13/18例无复发缓解并进入随访研究。
- 2/13例分别在第72、187和200周出现轻度复发,重启托珠单抗单药治疗后均达缓解。
- 第208周11/18例维持无复发缓解,11/13例药物-free缓解持续156周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The GUSTO [GCA treatment with Ultra-Short glucocorticoids (GC) and TOcilizumab] trial was set up to evaluate the efficacy and safety of a 52-week tocilizumab (TCZ) monotherapy after a 3-day GC-pulse in new-onset GCA. The presented data show the maintenance effect of the GUSTO protocol over 3 years and the effectiveness or retreatment with TCZ after relapse. METHODS: Eighteen patients with newly diagnosed GCA received 500 mg methylprednisolone i.v. for three consecutive days followed by TCZ monotherapy from day 3 until week 52 in a single-arm, single-centre, open-label clinical trial. Patients in clinical remission stopped TCZ at week 52. Maintenance of efficacy included the proportion of patients with complete lasting remission of disease at week 208. RESULTS: Median age was 72 (interquartile range 67-75) years at inclusion and 15/18 patients complained of cranial symptoms. At week 52, 13/18 patients were in relapse-free remission and entered the follow-up study. Minor relapses were observed in 2/13 patients at weeks 72, 187 and 200. In both patients, remission was achieved after restart of TCZ monotherapy. At week 208, 11/18 patients stayed in relapse-free remission; 11/13 patients remained in drug-free remission for 156 weeks. CONCLUSION: Drug-free remission was maintained in all but two patients entering long-term extension. This relapse rate is substantially lower than reported in the randomized controlled trials. Patient characteristics (exclusively new diagnoses), and the intensive initial treatment may explain the lasting remission.
引用
- Christ L, Seitz L, Scholz G, et al. Efficacy of tocilizumab monotherapy after ultrashort glucocorticoid administration to treat giant cell arteritis: three-year follow-up. Rheumatology (Oxford). 2025. PMID: 40478774. doi:10.1093/rheumatology/keaf317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。